Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 14/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848351 | 0.84 | RYR2 (0.62) | RYR2MAPK1ESR2NR1H2 | |
| SCHEMBL806952 | 0.84 | RYR2 (0.48) | RYR2MAPK1ESR2NR1H2 | |
| SCHEMBL6866549 | 0.83 | RYR2 (0.50) | RYR2MAPK1ESR2NR1H2 | |
| SCHEMBL807127 | 0.83 | ESR2 (0.65) | RYR2MAPK1ESR2NR1H2 | |
| SCHEMBL13622119 | 0.83 | RYR2 (0.54) | RYR2 | |
| SCHEMBL28455483 | 0.82 | ESR2 (0.51) | RYR2MAPK1ESR2NR1H2 | |
| SCHEMBL6867132 | 0.81 | RYR2 (0.70) | RYR2 | |
| SCHEMBL23124526 | 0.81 | ESR2 (0.69) | MAPK1ESR2USP30NR1H2CRBN | |
| SCHEMBL7744185 | 0.81 | NR1H2 (0.67) | MAPK1ESR2USP30NR1H2CRBN | |
| SCHEMBL30593270 | 0.81 | ESR2 (0.69) | MAPK1ESR2USP30NR1H2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230386615-A1 | BINDING SITE IN TYPE 1 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-30 | — | — | US | disclosed |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2023-11-16 | — | — | US | disclosed |
| WO-2023070091-A1 | A METHOD OF TREATING ESSENTIAL TREMOR BY TARGETING LEAKY RyR1 CHANNELS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-2764867-A1 | Agents for preventing and treating disorders Involving modulation of the RYR receptors | The Trustees of Columbia University in the City of New York (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-03 | — | — | US | disclosed |
| US-8710045-B2 | Agents for preventing and treating disorders involving modulation of the ryanodine receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710045-B2 | Agents for preventing and treating disorders involving modulation of the ryanodine receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2012037105-A1 | METHODS OF TREATING, AMELIORATING OR PREVENTING STRESS-INDUCED NEURONAL DISORDERS AND DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012019076-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CARDIAC ISCHEMIA/REPERFUSION INJURY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-07-14 | — | — | US | disclosed |
| EP-2311464-A1 | Agents for preventing and treating disorders involving modulation of the ryr receptors | The Trustees of Columbia University in the City of New York (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-7704990-B2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2177224-A2 | Agents for preventing and treating disorders involving modulation of the RyR receptors | The Trustees of Columbia University in the City of New York (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2008021432-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CONDITIONS AFFECTING THE NERVOUS SYSTEM | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021439-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIAC HYPERTROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| WO-2007024717-A2 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | RYR2 2/4885MAPK1 2539/4885ESR2 1935/4885 |
| US-20140187536-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR2, RYR1, FKBP3 | RYR2 1/4885MAPK1 1515/4885ESR2 3709/4885 |
| US-20230368862-A1 | BINDING SITE IN TYPE 2 RYANODINE RECEPTOR | RYR2, RYR1, ATP2A2 | RYR2 1/4885MAPK1 4303/4885ESR2 770/4885 |
| US-20110172190-A1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYANODINE RECEPTORS | RYR1, RYR2, ATP2A1 | RYR2 2/4885MAPK1 2543/4885ESR2 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.